Erdogan Iyigun Zeynep, Selamoglu Derya, Alco Gul, Pilancı Kezban Nur, Ordu Cetin, Agacayak Filiz, Elbüken Filiz, Bozdogan Atilla, Ilgun Serkan, Guler Uysal Fusun, Ozmen Vahit
1 Department of Physical Therapy and Rehabilitation and 4Medical Oncology, Istanbul Bilim University , Istanbul, Turkey .
Lymphat Res Biol. 2015 Mar;13(1):40-5. doi: 10.1089/lrb.2014.0014. Epub 2014 Dec 19.
The aim of this study was to evaluate the efficacy of bioimpedance spectroscopy for the follow-up of patients with lymphedema in Turkey and its benefits in the diagnosis of stage 0, 1, and 2 lymphedema in patients who are under treatment for breast cancer. Thirty-seven female patients with breast cancer who underwent surgical procedures in our Breast Health Centre were followed up for lymphedema using bioimpedance, and clinical measurements were taken for a minimum period of 1 year at 3-month intervals. Patients who had been monitored regularly between November, 2011, and September, 2013, were enrolled to the study. In total, 8 patients developed lymphedema with an overall rate of 21.6%. Among the 8 patients who developed lymphedema, 4 had Stage 2, 1 had Stage 1, and 3 had Stage 0 lymphedema. Stage 0 lymphedema could not be detected with clinical measurements. During the patients' 1-year follow-up period using measurements of bioimpedance, a statistically significant relationship was observed between the occurrence of lymphedema and the disease characteristics. including the number of the extracted and remaining lymph nodes and the region of radiotherapy (p=0.042, p=0.024, p=0.040). Bioimpedance analysis seems to be a practical and reliable method for the early diagnosis of lymphedema. It is believed that regular monitoring of patients in the high-risk group using bioimpedance analyses increases the ability to treat lymphedema.
本研究的目的是评估生物电阻抗光谱法在土耳其对淋巴水肿患者进行随访的疗效,以及其在乳腺癌治疗患者0期、1期和2期淋巴水肿诊断中的益处。在我们的乳腺健康中心接受手术的37名女性乳腺癌患者,采用生物电阻抗法对淋巴水肿进行随访,并每隔3个月进行一次临床测量,至少持续1年。2011年11月至2013年9月期间接受定期监测的患者被纳入本研究。共有8名患者发生淋巴水肿,总发生率为21.6%。在发生淋巴水肿的8名患者中,4例为2期,1例为1期,3例为0期淋巴水肿。临床测量无法检测出0期淋巴水肿。在患者使用生物电阻抗测量的1年随访期内,观察到淋巴水肿的发生与疾病特征之间存在统计学显著关系。包括切除和剩余淋巴结的数量以及放疗区域(p = 0.042,p = 0.024,p = 0.040)。生物电阻抗分析似乎是淋巴水肿早期诊断的一种实用且可靠的方法。据信,使用生物电阻抗分析对高危组患者进行定期监测可提高治疗淋巴水肿的能力。